This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Drs Li and Geskey have disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.
Investigators from multiple pediatric rheumatology centers conducted an international double-blind, placebo-controlled randomized clinical trial of tocilizumab (an anti-interleukin- 6 receptor antibody) for the treatment of systemic juvenile idiopathic arthritis (JIA).1 Patients were evaluated for response or flare according to JIA American College of Rheumatology (ACR) criteria, in which a JIA ACR30 response means the patient had 30% or greater improvement in at least 3 of 6 parameters (number of joints …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.